Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$72.43-0.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Bio-Techne improves profit margins from 12.2% to 24.2% in one year. It keeps paying a steady dividend of $0.08 per share. The acquisition by Merck KGaA boosts growth and market position. Revenue is stable near $311 million despite market challenges.
Revenue declined 2% year over year, showing weak growth. Leadership changes in Diagnostics may hurt execution. The stock trades at a high price-to-earnings ratio of 37.6, risking valuation pressure.
The market expects about 4.5% revenue growth and prices the stock roughly 32% above our estimate of intrinsic value. Our estimate is below the Street median by 17%, reflecting a more cautious outlook on growth and profitability.
Breaks if: Dividend per share falls below $0.08
Continue paying a quarterly cash dividend of $0.08 per share as part of capital allocation strategy.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on revenue growth and profitability. The current thesis state is intact, as recent earnings performance has been strong, but there are mixed signals regarding management's ability to maintain growth and profitability.
The valuation is considered expensive compared to peers, with a premium of 1.16. The market seems to have high expectations, as indicated by a significant expectations gap of 0.31, suggesting that investors are pricing in continued strong performance.
Fundamentals are likely to remain stable, with management focused on achieving revenue growth and maintaining profitability. However, there is a moderate risk of missing earnings expectations, especially given the recent trend of industry peers underperforming.
The thesis hinges on the ability of sector leaders to continue delivering strong earnings and guidance. Additionally, any cuts to guidance from TECH or a weakening jobs report could negatively impact sentiment and performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports revenue growth objectives. This reinforces the positive outlook for the company.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 6 of last 6 quarters. Dividend per share consistently maintained at $0.08 from 2025-Q3 through 2026-Q4. Management has reiterated this capital allocation commitment with no change, indicating steady delivery on this priority.
“Announced a cash dividend of $0.08 per share.”
“Dividend per share was $0.08.”
“Dividend per share was $0.08.”
“Dividend per share was $0.08.”
“Dividend per share was $0.08.”
“Dividend per share was $0.08.”
Breaks if: Operating margin falls below 15% in 2026-Q3
Breaks if: Revenue falls below $295 million in 2026-Q3
Breaks if: Material integration problems or loss of key customers reported
Over the next 1 to 3 years, TECH's performance will depend on its ability to navigate sector dynamics and manage growth effectively. Not investment advice.